Table 1.
Characteristics of patients and controls included in the study.
| Characteristics | Active GO patients (n = 17) | Inactive GO patients (n = 8) | Controls (n = 15) | GD without GO (n = 8) |
|---|---|---|---|---|
| Age at study enrollment, mean ± SD | 54.53 ± 10.86 | 50 ± 16.37 | 43.73 ± 19.713 | 53.13 ± 16.35 |
| Gender | ||||
| Female | 14 | 7 | 12 | 6 |
| Male | 3 | 1 | 3 | 2 |
| TSH (mIU/L) | 1.10 ± 1.52 | 1.29 ± 1.6 | 1.32 ± 0.42 | 0.49 ± 1.34 |
| Free T3 (pg/mL) | 4.52 ± 3.86 | 5.63 ± 7.81 | 3.01 ± 0.55 | 7.12 ± 4.66 |
| Free T4 (ng/dL) | 1.29 ± 0.76 | 1.73 ± 1.74 | 1.26 ± 0.14 | 2.12.±1.31 |
| Euthyroida | ||||
| Yes | 12 | 5 | 15 | 1 |
| No | 5 | 3 | 0 | 7 |
| TR-Abb (IU/L) | ||||
| Positive | 17 | 6 | 0 | 8 |
| Negative | 0 | 2 | 9 | 0 |
| Unknown | 0 | 0 | 6 | 0 |
| TPO-Abc (IU/mL) | ||||
| Positive | 8 | 4 | 0 | 6 |
| Negative | 9 | 3 | 9 | 0 |
| Unknown | 0 | 1 | 6 | 1 |
| Tg-Abd (IU/mL) | ||||
| Positive | 5 | 4 | 0 | 3 |
| Negative | 12 | 3 | 9 | 3 |
| Unknown | 0 | 1 | 6 | 2 |
| CAS | ||||
| >3 | 17 | 0 | ||
| <3 | 0 | 8 | ||
| Antithyroid treatment | ||||
| Yes | 15 | 3 | 7 | |
| No | 2 | 5 | 1 | |
| L-Thyroxine | ||||
| Yes | 1 | 2 | 0 | |
| No | 16 | 6 | 8 | |
| 131I | ||||
| Yes | 2 | 0 | 0 | |
| No | 15 | 8 | 8 | |
| Surgery | ||||
| Yes | 1 | 1 | 0 | |
| No | 16 | 7 | 8 | |
| Smoking | ||||
| Yes | 14 | 3 | 1 | |
| No | 0 | 5 | 0 | |
| Unknown | 3 | 0 | 7 | |
| MRI | ||||
| Active | 12 | 0 | ||
| Inactive | 0 | 6 | ||
| Unknown | 5 | 2 | ||
aPatients were considered euthyroid when TSH is 0.27–4.2 mIU/L, FT3 is 2.6-4.4 pg/mL, and FT4 is 0.93–1.7 ng/dL. bTR-Ab TSH receptor antibody, negative <1.75 IU/L. cTPO-Ab thyroid peroxidase antibody, negative <34 IU/mL. dTg-Ab thyroglobulin antibody, negative <115 IU/mL.